Press Releases

April 21, 2021
Ocugen’s COVID-19 Vaccine Co-Development Partner, Bharat Biotech, Shares Second Interim Results demonstrating 100% Protection against Severe Disease including Hospitalization
Primary efficacy in the second interim analysis demonstrates COVAXIN to be 78% effective after the second dose in preventing COVID-19 in those without prior infection Demonstrates 70% efficacy against asymptomatic COVID-19 infections; indicates potential to significantly reduce virus transmission
Additional Formats
March 18, 2021
Ocugen Provides Business Update and Full Year 2020 Financial Results
Conference Call and Webcast Today at 8:30 a.m. ET COVID-19 vaccine candidate, COVAXIN™, demonstrates efficacy of 81% in Phase 3 interim results Emergency Use Authorization pathway with U.S. regulatory authorities in development for COVAXIN™ European Commission grants orphan medicinal product
Additional Formats
March 8, 2021
Ocugen Inc. to Present at Upcoming March Investor Conferences
MALVERN, Pa., March 08, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that it will present at
Additional Formats
Displaying 21 - 30 of 38